Search results

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to standard of care.1

News centre

03 July, 2024

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Phase 3 PAPILLON study showed RYBREVANT® in combination with carboplatin and pemetrexed significantly improved progression-free survival, reducing the risk of disease progression or death by 60 per cent versus carboplatin and pemetrexed alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations.1

News centre

14 September, 2023

Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide

News centre

21 August, 2023

ERLEADA® (apalutamide) 240 mg Approved as the Only Androgen Receptor Inhibitor with a Once-Daily Single-Tablet Option in Canada

Health Canada’s approval of a new 240mg strength tablet will provide patients and their care providers with additional dosing options to address a variety of treatment needs

News centre

21 August, 2023

Health Canada Authorizes TECVAYLITM (teclistamab injection), a First-in-Class Bispecific Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Approval for TECVAYLITM, a subcutaneously administered therapy, is based on results from the Phase 1/2 MajesTEC-1 study that showed deep and durable responses in triple-class exposed patients with relapsed or refractory multiple myeloma.1

News centre

15 June, 2023

Health Canada Authorizes AKEEGATM (niraparib and abiraterone acetate) Dual Action Tablets for Targeted Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with BRCA (1/2) Gene Mutations

Approval for AKEEGATM is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated metastatic castration-resistant prostate cancer (mCRPC)1,2 Niraparib in combination with abiraterone acetate plus prednisone or prednisolone (AAP), showed significant improvement in radiographic progression-free survival (rPFS) compared to AAP in mCRPC patients with BRCA1/2 mutations3

You are now leaving J&J Innovative Medicine Canada.

You are now leaving J&J Innovative Medicine Canada.

You are now leaving J&J Innovative Medicine Canada.

You are now leaving J&J Innovative Medicine Canada.

You are now leaving J&J Innovative Medicine Canada.

You are now leaving J&J Innovative Medicine Canada.

No Results

Search results - Johnson & Johnson Innovative Medicine Canada